Boosting antibody developability through rational sequence optimization

The application of monoclonal antibodies as commercial therapeutics poses substantial demands on stability and properties of an antibody. Therapeutic molecules that exhibit favorable properties increase the success rate in development. However, it is not yet fully understood how the protein sequences of an antibody translates into favorable in vitro molecule properties. In this work, computational design strategies based on heuristic sequence analysis were used to systematically modify an antibody that exhibited a tendency to precipitation in vitro. The resulting series of closely related antibodies showed improved stability as assessed by biophysical methods and long-term stability experiments. As a notable observation, expression levels also improved in comparison with the wild-type candidate. The methods employed to optimize the protein sequences, as well as the biophysical data used to determine the effect on stability under conditions commonly used in the formulation of therapeutic proteins, are described. Together, the experimental and computational data led to consistent conclusions regarding the effect of the introduced mutations. Our approach exemplifies how computational methods can be used to guide antibody optimization for increased stability.

[1]  P. Callis,et al.  Mechanisms of tryptophan fluorescence shifts in proteins. , 2001, Biophysical journal.

[2]  Silvio C. E. Tosatto,et al.  The PASTA server for protein aggregation prediction. , 2007, Protein engineering, design & selection : PEDS.

[3]  Michele Vendruscolo,et al.  Prediction of aggregation-prone regions in structured proteins. , 2008, Journal of molecular biology.

[4]  Matthias J. Feige,et al.  An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. , 2009, Molecular cell.

[5]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[6]  D. Röthlisberger,et al.  Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. , 2005, Journal of molecular biology.

[7]  Bert L de Groot,et al.  Geometry-based sampling of conformational transitions in proteins. , 2007, Structure.

[8]  Elizabeth M. Topp,et al.  Chemical Instability in Peptide and Protein Pharmaceuticals , 2010 .

[9]  G. Gilliland,et al.  Structure-based engineering of a monoclonal antibody for improved solubility. , 2010, Protein engineering, design & selection : PEDS.

[10]  T. Tiller,et al.  Characterization and screening of IgG binding to the neonatal Fc receptor , 2014, mAbs.

[11]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[12]  Christopher J Roberts,et al.  Conformational stability as a design target to control protein aggregation. , 2014, Protein engineering, design & selection : PEDS.

[13]  Colleen E. Price,et al.  Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[14]  P. Garidel,et al.  A rapid, sensitive and economical assessment of monoclonal antibody conformational stability by intrinsic tryptophan fluorescence spectroscopy , 2008, Biotechnology journal.

[15]  Yvonne Stark,et al.  A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties , 2013, mAbs.

[16]  D. Baker,et al.  Role of conformational sampling in computing mutation‐induced changes in protein structure and stability , 2011, Proteins.

[17]  Janice M Reichert,et al.  Antibodies to watch in 2014 , 2014, mAbs.

[18]  Suzanne S Farid,et al.  Process economics of industrial monoclonal antibody manufacture. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[19]  J F Brandts,et al.  A simple model for proteins with interacting domains. Applications to scanning calorimetry data. , 1989, Biochemistry.

[20]  Andrew G. W. Leslie,et al.  Processing diffraction data with mosflm , 2007 .

[21]  Wei Wang,et al.  Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.

[22]  Bernhardt L. Trout,et al.  Design of therapeutic proteins with enhanced stability , 2009, Proceedings of the National Academy of Sciences.

[23]  T. Laird.  Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals , 2013 .

[24]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[25]  Sebastian Doniach,et al.  A comparative study of motor-protein motions by using a simple elastic-network model , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Gregory A Voth,et al.  Coarse-grained modeling of the self-association of therapeutic monoclonal antibodies. , 2012, The journal of physical chemistry. B.

[27]  Norman J Wagner,et al.  Observation of small cluster formation in concentrated monoclonal antibody solutions and its implications to solution viscosity. , 2014, Biophysical journal.

[28]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[29]  Gerhard Winter,et al.  A critical evaluation of microcalorimetry as a predictive tool for long term stability of liquid protein formulations: granulocyte colony stimulating factor (GCSF). , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[30]  William F Weiss,et al.  Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.

[31]  Amedeo Caflisch,et al.  Prediction of aggregation rate and aggregation‐prone segments in polypeptide sequences , 2005, Protein science : a publication of the Protein Society.

[32]  Francesc X. Avilés,et al.  AGGRESCAN: a server for the prediction and evaluation of "hot spots" of aggregation in polypeptides , 2007, BMC Bioinform..

[33]  Christopher J Roberts,et al.  Therapeutic protein aggregation: mechanisms, design, and control. , 2014, Trends in biotechnology.

[34]  S. Demarest,et al.  A broad range of Fab stabilities within a host of therapeutic IgGs. , 2007, Biochemical and biophysical research communications.

[35]  Daniel Seeliger,et al.  Development of Scoring Functions for Antibody Sequence Assessment and Optimization , 2013, PloS one.

[36]  Fred Jacobson,et al.  Protein aggregation and bioprocessing , 2006, The AAPS Journal.

[37]  Karsten Suhre,et al.  ElNémo: a normal mode web server for protein movement analysis and the generation of templates for molecular replacement , 2004, Nucleic Acids Res..

[38]  L. Serrano,et al.  Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins , 2004, Nature Biotechnology.

[39]  L. Serrano,et al.  Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. , 2002, Journal of molecular biology.

[40]  P. Parren,et al.  The IgG Fc Contains Distinct Fc Receptor (FcR) Binding Sites: The Leukocyte Receptors FcγRI and FcγRIIa Bind to a Region in the Fc Distinct from That Recognized by Neonatal FcR and Protein A1 , 2000, The Journal of Immunology.

[41]  Vidyashankara G. Iyer,et al.  High throughput prediction of the long-term stability of pharmaceutical macromolecules from short-term multi-instrument spectroscopic data. , 2014, Journal of pharmaceutical sciences.

[42]  Clemens Vonrhein,et al.  Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.

[43]  Steven J Shire,et al.  Challenges in the development of high protein concentration formulations. , 2004, Journal of pharmaceutical sciences.

[44]  S. Jones,et al.  Prediction of protein-protein interaction sites using patch analysis. , 1997, Journal of molecular biology.

[45]  E. Rowe.  Dissociation and denaturation equilibria and kinetics of a homogeneous human immunoglobulin Fab fragment. , 1976, Biochemistry.

[46]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.

[47]  Christopher J Roberts,et al.  Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions. , 2011, Journal of pharmaceutical sciences.

[48]  E. A. Burstein,et al.  FLUORESCENCE AND THE LOCATION OF TRYPTOPHAN RESIDUES IN PROTEIN MOLECULES , 1973, Photochemistry and photobiology.

[49]  Bert L de Groot,et al.  Protein thermostability calculations using alchemical free energy simulations. , 2010, Biophysical journal.

[50]  Randy J. Read,et al.  Evolving Methods for Macromolecular Crystallography , 2007 .